Skip to content

Opus Genetics IRD Stock-Based Comp

Stock-Based Comp at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's stock-based comp?
Opus Genetics (IRD) reported stock-based comp of $1.46M in Q1 2026.
How has Opus Genetics's stock-based comp changed year-over-year?
Opus Genetics's stock-based comp increased by 60.4% year-over-year, from $913K to $1.46M.
What is the long-term trend for Opus Genetics's stock-based comp?
Over 4 years (2021 to 2025), Opus Genetics's stock-based comp has grown at a 15.4% compound annual growth rate (CAGR), from $1.91M to $3.4M.